このエントリーをはてなブックマークに追加
ID 31972
JaLCDOI
フルテキストURL
著者
Hiramatsu, Yuji Okayama University
Masuyama, Hisashi Okayama University
Ishida, Makoto Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
Murakami, Kazuharu Tamashima Central Hospital
Sakurai, Masaru Tamashima Central Hospital
抄録

It is well known that antecedent term delivery and metastasis to sites other than the lungs and vagina are high risk factors for patients with gestational trophoblastic neoplasia. Here we report on a patient with choriocarcinoma who presented with brain and lung metastases after term delivery and was treated by EMA-CO chemotherapy. A 31-year-old woman delivered a healthy infant at term. Frequent episodes of hemoptysis occurred beginning 3 weeks after the delivery. On admission to our hospital, she had lesions in the uterus, lungs and brain as well as motor aphasia and hemiplagia. The pretreatment beta-hCG level was 21,000 ng/ml and the WHO score was 16 (high-risk group). The EMA-CO regimen was administrated as first-line chemotherapy and the patient achieved complete remission after 7 courses. Treatment was terminated after 11 courses and maintained with etoposide (25 mg/day) for 6 months. The patient has remained in complete remission for more than 16 years without other adjuvant therapies. We believe that EMA-CO can currently be considered the regimen of first choice for most high-risk patients with gestational trophoblastic neoplasia in view of its effectiveness and excellent tolerability.

キーワード
choriocarcinoma
term delivery
EMA-CO chemotherapy
metastasis
Amo Type
Article
発行日
2005-10
出版物タイトル
Acta Medica Okayama
59巻
5号
出版者
Okayama University Medical School
開始ページ
253
終了ページ
258
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
English
OAI-PMH Set
岡山大学
論文のバージョン
publisher
査読
有り
Submission Path
amo/vol59/iss5/9
PubMed ID
Web of Sience KeyUT